Niall C. Tebbutt

发表

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

E. Van Cutsem, A. Grothey, F. Kabbinavar, 2023, Cancers.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

D. Tu, M. Moore, J. Zalcberg, 2015, European journal of cancer.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

C. Underhill, S. Brule, C. O'Callaghan, 2015, European journal of cancer.

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

E. Saad, E. Van Cutsem, J. Tabernero, 2021, Journal of the National Cancer Institute.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

M. Stockler, V. Gebski, R. Simes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

V. Gebski, D. Goldstein, J. Zalcberg, 2011, European journal of cancer.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

M. Stockler, V. Gebski, J. Zalcberg, 2010, British Journal of Cancer.

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

P. Gibbs, L. Lipton, J. Zalcberg, 2013, Cancer Chemotherapy and Pharmacology.

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer.

K. Kinzler, B. Vogelstein, P. Gibbs, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

V. Gebski, D. Goldstein, J. Zalcberg, 2016, Cancer Chemotherapy and Pharmacology.

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity

N. Tebbutt, G. Chong, Niall C. Tebbutt, 2010, Therapeutic advances in medical oncology.